Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Clinical trial NCT00423046 · COMPLETED

Trial details

NCT number: NCT00423046
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Infections, Papillomavirus Papillomavirus Vaccines

Start date: 2007-01-24
Primary completion: 2008-03-07
Enrollment: 1106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.